Stay updated with breaking news from 03152w10. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) – Zacks Research decreased their Q3 2024 earnings estimates for shares of Amicus Therapeutics in a report issued on Thursday, January 18th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their prior estimate of $0.01. […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) – Equities researchers at Zacks Research lowered their Q3 2024 EPS estimates for Amicus Therapeutics in a research note issued to investors on Thursday, January 18th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) insider David Michael Clark sold 1,384 shares of Amicus Therapeutics stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $14.00, for a total value of $19,376.00. Following the completion of the sale, the insider now owns 266,705 shares of […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) CEO Bradley L. Campbell sold 15,833 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.23, for a total transaction of $225,303.59. Following the transaction, the chief executive officer now owns 947,805 shares of the […]